@article{KaemmererTribiusCohrsetal.2023,
  author    = {K{\"a}mmerer, Peer W. and Tribius, Silke and Cohrs, Lena and Engler, Gabriel and Ettl, Tobias and Freier, Kolja and Frerich, Bernhard and Ghanaati, Shahram and Gosau, Martin and Haim, Dominik and Hartmann, Stefan and Heiland, Max and Herbst, Manuel and Hoefert, Sebastian and Hoffmann, J{\"u}rgen and H{\"o}lzle, Frank and Howaldt, Hans-Peter and Kreutzer, Kilian and Leonhardt, Henry and Lutz, Rainer and Moergel, Maximilian and Modabber, Ali and Neff, Andreas and Pietzka, Sebastian and Rau, Andrea and Reichert, Torsten E. and Smeets, Ralf and Sproll, Christoph and Steller, Daniel and Wiltfang, J{\"o}rg and Wolff, Klaus-Dietrich and Kronfeld, Kai and Al-Nawas, Bilal},
  title     = {Adjuvant radiotherapy in patients with squamous cell carcinoma of the oral cavity or oropharynx and solitary ipsilateral lymph node metastasis (pN1) — a prospective multicentric cohort study},
  series = {Cancers},
  volume    = {15},
  journal   = {Cancers},
  number    = {6},
  issn      = {2072-6694},
  doi       = {10.3390/cancers15061833},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-311024},
  year      = {2023},
  abstract  = {(1) Background: Evaluation of impact of adjuvant radiation therapy (RT) in patients with oral squamous cell carcinoma of the oral cavity/oropharynx (OSCC) of up to 4 cm (pT1/pT2) and solitary ipsilateral lymph node metastasis (pN1). A non-irradiated group with clinical follow-up was chosen for control, and survival and quality of life (QL) were compared; (2) Methods: This prospective multicentric comprehensive cohort study included patients with resected OSCC (pT1/pT2, pN1, and cM0) who were allocated into adjuvant radiation therapy (RT) or observation. The primary endpoint was overall survival. Secondary endpoints were progression-free survival and QL after surgery; (3) Results: Out of 27 centers, 209 patients were enrolled with a median follow-up of 3.4 years. An amount of 137 patients were in the observation arm, and 72 received adjuvant irradiation. Overall survival did not differ between groups (hazard ratio (HR) 0.98 [0.55-1.73], p = 0.94). There were fewer neck metastases (HR 0.34 [0.15-0.77]; p = 0.01), as well as fewer local recurrences (HR 0.41 [0.19-0.89]; p = 0.02) under adjuvant RT. For QL, irradiated patients showed higher values for the symptom scale pain after 0.5, two, and three years (all p < 0.05). After six months and three years, irradiated patients reported higher symptom burdens (impaired swallowing, speech, as well as teeth-related problems (all p < 0.05)). Patients in the RT group had significantly more problems with mouth opening after six months, one, and two years (p < 0.05); (4) Conclusions: Adjuvant RT in patients with early SCC of the oral cavity and oropharynx does not seem to influence overall survival, but it positively affects progression-free survival. However, irradiated patients report a significantly decreased QL up to three years after therapy compared to the observation group.},
  language  = {en}
}
@article{AltieriLaSalviaModicaetal.2023,
  author    = {Altieri, Barbara and La Salvia, Anna and Modica, Roberta and Marciello, Francesca and Mercier, Olaf and Filosso, Pier Luigi and de Latour, Bertrand Richard and Giuffrida, Dario and Campione, Severo and Guggino, Gianluca and Fadel, Elie and Papotti, Mauro and Colao, Annamaria and Scoazec, Jean-Yves and Baudin, Eric and Faggiano, Antongiulio},
  title     = {Recurrence-free survival in early and locally advanced large cell neuroendocrine carcinoma of the lung after complete tumor resection},
  series = {Journal of Personalized Medicine},
  volume    = {13},
  journal   = {Journal of Personalized Medicine},
  number    = {2},
  issn      = {2075-4426},
  doi       = {10.3390/jpm13020330},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-304000},
  year      = {2023},
  abstract  = {Background: Large Cell Neuroendocrine Carcinoma (LCNEC) is a rare subtype of lung cancer with poor clinical outcomes. Data on recurrence-free survival (RFS) in early and locally advanced pure LCNEC after complete resection (R0) are lacking. This study aims to evaluate clinical outcomes in this subgroup of patients and to identify potential prognostic markers. Methods: Retrospective multicenter study including patients with pure LCNEC stage I-III and R0 resection. Clinicopathological characteristics, RFS, and disease-specific survival (DSS) were evaluated. Univariate and multivariate analyses were performed. Results: 39 patients (M:F = 26:13), with a median age of 64 years (44-83), were included. Lobectomy (69.2\%), bilobectomy (5.1\%), pneumonectomy (18\%), and wedge resection (7.7\%) were performed mostly associated with lymphadenectomy. Adjuvant therapy included platinum-based chemotherapy and/or radiotherapy in 58.9\% of cases. After a median follow-up of 44 (4-169) months, the median RFS was 39 months with 1-, 2- and 5-year RFS rates of 60.0\%, 54.6\%, and 44.9\%, respectively. Median DSS was 72 months with a 1-, 2- and 5-year rate of 86.8, 75.9, and 57.4\%, respectively. At multivariate analysis, age (cut-off 65 years old) and pN status were independent prognostic factors for both RFS (HR = 4.19, 95\%CI = 1.46-12.07, p = 0.008 and HR = 13.56, 95\%CI 2.45-74.89, p = 0.003, respectively) and DSS (HR = 9.30, 95\%CI 2.23-38.83, p = 0.002 and HR = 11.88, 95\%CI 2.28-61.84, p = 0.003, respectively). Conclusion: After R0 resection of LCNEC, half of the patients recurred mostly within the first two years of follow-up. Age and lymph node metastasis could help to stratify patients for adjuvant therapy.},
  language  = {en}
}
@phdthesis{vonBosse2022,
  author    = {von Bosse, Felix},
  title     = {Risikofaktoren der venoarteriellen extrakorporalen Membranoxygenierung bei Post-Kardiotomie-Patienten},
  doi       = {10.25972/OPUS-25819},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-258198},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2022},
  abstract  = {Die extrakorporale Membranoxygenierung ist ein seit Jahrzehnten etabliertes Verfahren, Patienten trotz kardialem und/oder pulmonalem Versagen ein zeitbegrenztes {\"U}berleben zu erm{\"o}glichen. Obgleich sich an den Grundz{\"u}gen der Herangehensweise bis heute wenig ver{\"a}ndert hat, konnte diese Hochrisikotherapie mithilfe der Entwicklung blutschonenderer Materialien und der Verwendung verbesserter Pumpen und Oxygenatoren zunehmend effizienter gestaltet werden. Durch eine {\"U}berlebensanalyse aller ECMO-Patienten der Datenbank der Klinik f{\"u}r Tho-rax-, Herz- und Thorakale Gef{\"a}ßchirurgie des Universit{\"a}tsklinikums W{\"u}rzburg zwischen 2015 und 2018 (172 F{\"a}lle) sollten unabh{\"a}ngige Risikofaktoren f{\"u}r ein negatives Outcome der Therapie identifiziert werden. Insbesondere den Laborparametern w{\"a}hrend der ersten 72 Stunden am System galt hierbei ein besonderes Augenmerk, aber auch Vorerkrankun-gen, Komplikationen, Substitutionen w{\"a}hrend der Therapie und weitere Parameter wurden f{\"u}r jeden Patienten individuell ermittelt und tabellarisch festgehalten. Insgesamt verstarben davon 125 Patienten (72,7\%), 47 Patienten (27,3\%) {\"u}berlebten und konnten entlassen werden. Bei 24 der 125 verstorbenen Patienten (14\%) konnte zwar ein Weaning vom System erfolgreich durchgef{\"u}hrt werden (>24h), sie verstarben jedoch w{\"a}hrend des anschließenden station{\"a}ren Aufenthaltes. Bei den pr{\"a}insertionell erhobenen Parametern waren der BMI und der Euroscore II bei verstorbenen Patienten signifikant h{\"o}her, ebenso wie die Cross-Clamp-Zeit und der SO-FA-Score. F{\"u}r die Laborwerte an ECMO ergaben sich f{\"u}r den Serumlaktatspiegel und die Throm-bozytenanzahl der Patienten die signifikantesten Unterschiede. Auch andere Laborparame-ter erwiesen sich in beiden Gruppen als signifikant unterschiedlich: Insbesondere der Quick Wert der {\"u}berlebenden Patienten war zu Beginn signifikant h{\"o}her. Auch der Fibri-nogenspiegel der Gruppe der {\"u}berlebenden Patienten lag ab der 12 Stunden Marke signi-fikant h{\"o}her. Verstorbene Patienten erhielten mehr Blutpr{\"a}parate als {\"U}berlebende. Außerdem f{\"u}hrte ein dialysepflichtiges Nierenversagen im Laufe der Therapie zu signifikant schlechterem Out-come. Wider Erwarten waren w{\"a}hrend der Therapie auftretende Blutungskomplikationen nicht mit schlechterem Outcome assoziiert. Jedoch konnte bei Auftritt von Thromben im Sys-tem, die einen Austausch des Oxygenators/ECMO-Systems n{\"o}tig machten, sowie Magen-Darm-Isch{\"a}mien und Kompartmentsyndrom ein klarer {\"U}berlebensnachteil erfasst werden. Abschließend ließ sich mittels multivariater logistischer Regression zeigen, dass der SO-FA-Score, der Serumlaktatspiegel und die Thrombozytenanzahl sowie eine adjuvante I-ABP Implantation und der Bedarf einer Nierenersatztherapie den gr{\"o}ßten Einfluss auf das {\"U}berleben der Patienten hatten.},
  subject      = {ECMO},
  language  = {de}
}
@article{KoehlerAdamFussetal.2022,
  author    = {Koehler, Viktoria Florentine and Adam, Pia and Fuss, Carmina Teresa and Jiang, Linmiao and Berg, Elke and Frank-Raue, Karin and Raue, Friedhelm and Hoster, Eva and Kn{\"o}sel, Thomas and Schildhaus, Hans-Ulrich and Negele, Thomas and Siebolts, Udo and Lorenz, Kerstin and Allelein, Stephanie and Schott, Matthias and Spitzweg, Christine and Kroiss, Matthias},
  title     = {Treatment of RET-positive advanced medullary thyroid cancer with multi-tyrosine kinase inhibitors — a retrospective multi-center registry analysis},
  series = {Cancers},
  volume    = {14},
  journal   = {Cancers},
  number    = {14},
  issn      = {2072-6694},
  doi       = {10.3390/cancers14143405},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-281776},
  year      = {2022},
  abstract  = {Background: RET (rearranged during transfection) variants are the most prevalent oncogenic events in medullary thyroid cancer (MTC). In advanced disease, multi-tyrosine kinase inhibitors (MKIs) cabozantinib and vandetanib are the approved standard treatment irrespective of RET status. The actual outcome of patients with RET-positive MTC treated with MKIs is ill described. Methods: We here retrospectively determined the RET oncogene variant status with a targeted DNA Custom Panel in a prospectively collected cohort of 48 patients with advanced MTC treated with vandetanib and/or cabozantinib at four German referral centers. Progression-free survival (PFS) and overall survival (OS) probabilities were estimated using the Kaplan-Meier method. Results: In total, 44/48 (92\%) patients had germline or somatic RET variants. The M918T variant was found in 29/44 (66\%) cases. In total, 2/32 (6\%) patients with a somatic RET variant had further somatic variants, while in 1/32 (3\%) patient with a germline RET variant, additional variants were found. Only 1/48 (2\%) patient had a pathogenic HRAS variant, and no variants were found in 3 cases. In first-line treatment, the median OS was 53 (95\% CI (95\% confidence interval), 32-NR (not reached); n = 36), and the median PFS was 21 months (12-39; n = 33) in RET-positive MTC patients. In second-line treatment, the median OS was 18 (13-79; n = 22), and the median PFS was 3.5 months (2-14; n = 22) in RET-positive cases. Conclusions: RET variants were highly prevalent in patients with advanced MTC. The treatment results in RET-positive cases were similar to those reported in unselected cohorts.},
  language  = {en}
}
@article{EckardtStasikKrameretal.2021,
  author    = {Eckardt, Jan-Niklas and Stasik, Sebastian and Kramer, Michael and R{\"o}llig, Christoph and Kr{\"a}mer, Alwin and Scholl, Sebastian and Hochhaus, Andreas and Crysandt, Martina and Br{\"u}mmendorf, Tim H. and Naumann, Ralph and Steffen, Bj{\"o}rn and Kunzmann, Volker and Einsele, Hermann and Schaich, Markus and Burchert, Andreas and Neubauer, Andreas and Sch{\"a}fer-Eckart, Kerstin and Schliemann, Christoph and Krause, Stefan W. and Herbst, Regina and H{\"a}nel, Mathias and Frickhofen, Norbert and Noppeney, Richard and Kaiser, Ulrich and Baldus, Claudia D. and Kaufmann, Martin and R{\´a}cil, Zdenek and Platzbecker, Uwe and Berdel, Wolfgang E. and Mayer, Jiř{\´i} and Serve, Hubert and M{\"u}ller-Tidow, Carsten and Ehninger, Gerhard and St{\"o}lzel, Friedrich and Kroschinsky, Frank and Schetelig, Johannes and Bornh{\"a}user, Martin and Thiede, Christian and Middeke, Jan Moritz},
  title     = {Loss-of-function mutations of BCOR are an independent marker of adverse outcomes in intensively treated patients with acute myeloid leukemia},
  series = {Cancers},
  volume    = {13},
  journal   = {Cancers},
  number    = {9},
  issn      = {2072-6694},
  doi       = {10.3390/cancers13092095},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-236735},
  year      = {2021},
  abstract  = {Acute myeloid leukemia (AML) is characterized by recurrent genetic events. The BCL6 corepressor (BCOR) and its homolog, the BCL6 corepressor-like 1 (BCORL1), have been reported to be rare but recurrent mutations in AML. Previously, smaller studies have reported conflicting results regarding impacts on outcomes. Here, we retrospectively analyzed a large cohort of 1529 patients with newly diagnosed and intensively treated AML. BCOR and BCORL1 mutations were found in 71 (4.6\%) and 53 patients (3.5\%), respectively. Frequently co-mutated genes were DNTM3A, TET2 and RUNX1. Mutated BCORL1 and loss-of-function mutations of BCOR were significantly more common in the ELN2017 intermediate-risk group. Patients harboring loss-of-function mutations of BCOR had a significantly reduced median event-free survival (HR = 1.464 (95\%-Confidence Interval (CI): 1.005-2.134), p = 0.047), relapse-free survival (HR = 1.904 (95\%-CI: 1.163-3.117), p = 0.01), and trend for reduced overall survival (HR = 1.495 (95\%-CI: 0.990-2.258), p = 0.056) in multivariable analysis. Our study establishes a novel role for loss-of-function mutations of BCOR regarding risk stratification in AML, which may influence treatment allocation.},
  language  = {en}
}
@article{SolgerKunzFinketal.2020,
  author    = {Solger, Franziska and Kunz, Tobias C. and Fink, Julian and Paprotka, Kerstin and Pfister, Pauline and Hagen, Franziska and Schumacher, Fabian and Kleuser, Burkhard and Seibel, J{\"u}rgen and Rudel, Thomas},
  title     = {A Role of Sphingosine in the Intracellular Survival of Neisseria gonorrhoeae},
  series = {Frontiers in Cellular and Infection Microbiology},
  volume    = {10},
  journal   = {Frontiers in Cellular and Infection Microbiology},
  issn      = {2235-2988},
  doi       = {10.3389/fcimb.2020.00215},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-204111},
  year      = {2020},
  abstract  = {Obligate human pathogenic Neisseria gonorrhoeae are the second most frequent bacterial cause of sexually transmitted diseases. These bacteria invade different mucosal tissues and occasionally disseminate into the bloodstream. Invasion into epithelial cells requires the activation of host cell receptors by the formation of ceramide-rich platforms. Here, we investigated the role of sphingosine in the invasion and intracellular survival of gonococci. Sphingosine exhibited an anti-gonococcal activity in vitro. We used specific sphingosine analogs and click chemistry to visualize sphingosine in infected cells. Sphingosine localized to the membrane of intracellular gonococci. Inhibitor studies and the application of a sphingosine derivative indicated that increased sphingosine levels reduced the intracellular survival of gonococci. We demonstrate here, that sphingosine can target intracellular bacteria and may therefore exert a direct bactericidal effect inside cells.},
  language  = {en}
}
@article{AssfalgSeligTolksdorfetal.2020,
  author    = {Assfalg, Volker and Selig, Katharina and Tolksdorf, Johanna and van Meel, Marieke and de Vries, Erwin and Ramsoebhag, Anne-Marie and Rahmel, Axel and Renders, Lutz and Novotny, Alexander and Matevossian, Edouard and Schneeberger, Stefan and Rosenkranz, Alexander R. and Berlakovich, Gabriela and Ysebaert, Dirk and Knops, No{\"e}l and Kuypers, Dirk and Weekers, Laurent and Muehlfeld, Anja and Rump, Lars-Christian and Hauser, Ingeborg and Pisarski, Przemyslaw and Weimer, Rolf and Fornara, Paolo and Fischer, Lutz and Kliem, Volker and Sester, Urban and Stippel, Dirk and Arns, Wolfgang and Hau, Hans-Michael and Nitschke, Martin and Hoyer, Joachim and Thorban, Stefan and Weinmann-Menke, Julia and Heller, Katharina and Banas, Bernhard and Schwenger, Vedat and Nadalin, Silvio and Lopau, Kai and H{\"u}ser, Norbert and Heemann, Uwe},
  title     = {Repeated kidney re-transplantation—the Eurotransplant experience: a retrospective multicenter outcome analysis},
  series = {Transplant International},
  volume    = {33},
  journal   = {Transplant International},
  number    = {6},
  doi       = {10.1111/tri.13569},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-214161},
  pages     = {617 -- 631},
  year      = {2020},
  abstract  = {In Eurotransplant kidney allocation system (ETKAS), candidates can be considered unlimitedly for repeated re-transplantation. Data on outcome and benefit are indeterminate. We performed a retrospective 15-year patient and graft outcome data analysis from 1464 recipients of a third or fourth or higher sequential deceased donor renal transplantation (DDRT) from 42 transplant centers. Repeated re-DDRT recipients were younger (mean 43.0 vs. 50.2 years) compared to first DDRT recipients. They received grafts with more favorable HLA matches (89.0\% vs. 84.5\%) but thereby no statistically significant improvement of patient and graft outcome was found as comparatively demonstrated in 1st DDRT. In the multivariate modeling accounting for confounding factors, mortality and graft loss after 3rd and ≥4th DDRT (P < 0.001 each) and death with functioning graft (DwFG) after 3rd DDRT (P = 0.001) were higher as compared to 1st DDRT. The incidence of primary nonfunction (PNF) was also significantly higher in re-DDRT (12.7\%) than in 1st DDRT (7.1\%; P < 0.001). Facing organ shortage, increasing waiting time, and considerable mortality on dialysis, we question the current policy of repeated re-DDRT. The data from this survey propose better HLA matching in first DDRT and second DDRT and careful selection of candidates, especially for ≥4th DDRT.},
  language  = {en}
}
@article{EbnerWoeckelSchwentneretal.2019,
  author    = {Ebner, Florian and W{\"o}ckel, Achim and Schwentner, Lukas and Blettner, Maria and Janni, Wolfgang and Kreienberg, Rolf and Wischnewsky, Manfred},
  title     = {Does the number of removed axillary lymphnodes in high risk breast cancer patients influence the survival?},
  series = {BMC Cancer},
  volume    = {19},
  journal   = {BMC Cancer},
  doi       = {10.1186/s12885-019-5292-2},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-226445},
  year      = {2019},
  abstract  = {Background The decision making process for axillary dissection has changed in recent years for patients with early breast cancer and positive sentinel lymph nodes (LN). The question now arises, what is the optimal surgical treatment for patients with positive axillary LN (pN+). This article tries to answer the following questions: (1) Is there a survival benefit for breast cancer patients with 3 or more positive LN (pN3+) and with more than 10 removed LN? (2) Is there a survival benefit for high risk breast cancer patients (triple negative or Her2 + breast cancer) and with 3 or more positive LN (pN3+) with more than 10 removed LN? (3) In pN + patients is the prognostic value of the lymph node ratio (LNR) of pN+/pN removed impaired if 10 or less LN are removed? Methods A retrospective database analysis of the multi center cohort database BRENDA (breast cancer under evidence based guidelines) with data from 9625 patients from 17 breast centers was carried out. Guideline adherence was defined by the 2008 German National consensus guidelines. Results 2992 out of 9625 patients had histological confirmed positive lymph nodes. The most important factors for survival were intrinsic sub types, tumor size and guideline adherent chemo- and hormonal treatment (and age at diagnosis for overall survival (OAS)). Uni-and multivariable analyses for recurrence free survival (RFS) and OAS showed no significant survival benefit when removing more than 10 lymph nodes even for high-risk patients. The mean and median of LNR were significantly higher in the pN+ patients with ≤10 excised LN compared to patients with > 10 excised LN. LNR was in both, uni-and multivariable, analysis a highly significant prognostic factor for RFS and OAS in both subgroups of pN + patients with less respective more than 10 excised LN. Multivariable COX regression analysis was adjusted by age, tumor size, intrinsic sub types and guideline adherent adjuvant systemic therapy. Conclusion The removal of more than 10 LN did not result in a significant survival benefit even in high risk pN + breast cancer patients.},
  language  = {en}
}
@article{BekesLoebHolzheuetal.2019,
  author    = {Bekes, Inga and L{\"o}b, Sanja and Holzheu, Iris and Janni, Wolfgang and Baumann, Lisa and W{\"o}ckel, Achim and Wulff, Christine},
  title     = {Nectin-2 in ovarian cancer: how is it expressed and what might be its functional role?},
  series = {Cancer Science},
  volume    = {110},
  journal   = {Cancer Science},
  number    = {6},
  doi       = {10.1111/cas.13992},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-202748},
  pages     = {1872- 1882},
  year      = {2019},
  abstract  = {Nectin-2 is an adhesion molecule that has been reported to play a role in tumor growth, metastasis and tumor angiogenesis. Herein, we investigated Nectin-2 in ovarian cancer patients and in cell culture. Tumor as well as peritoneal biopsies of 60 ovarian cancer patients and 22 controls were dual stained for Nectin-2 and CD31 using immunohistochemistry. Gene expression of Nectin-2 was quantified by real-time PCR and differences analyzed in relation to various tumor characteristics. In the serum of patients, vascular endothelial growth factor (VEGF) was quantified by ELISA. Effect of VEGF on Nectin-2 expression as well as permeability was investigated in HUVEC. In tumor biopsies, Nectin-2 protein was mainly localized in tumor cells, whereas in peritoneal biopsies, clear colocalization was found in the vasculature. T3 patients had a significantly higher percentage of positive lymph nodes and this correlated with survival. Nectin-2 was significantly upregulated in tumor biopsies in patients with lymph node metastasis and with residual tumor >1 cm after surgery. Nectin-2 expression was significantly suppressed in the peritoneal endothelium of patients associated with significantly increased VEGF serum levels. In cell culture, VEGF stimulation led to a significant downregulation of Nectin-2 which was reversed by VEGF-inhibition. In addition, Nectin-2 knockdown in endothelial cells was associated with significantly increased endothelial permeability. Nectin-2 expression in ovarian cancer may support tumor cell adhesion, leading to growth and lymph node metastasis. In addition, VEGF-induced Nectin-2 suppression in peritoneal endothelium may support an increase in vascular permeability leading to ascites production.},
  language  = {en}
}
@phdthesis{Horn2018,
  author    = {Horn, Johannes},
  title     = {Behandlungsergebnisse und Vergleich der Harnableitungsverfahren von exenterativen Eingriffen bei nicht-urothelialen Malignomen},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-169199},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2018},
  abstract  = {Die Zielsetzung dieser Studie ist, die operativen Daten, die Folgen, die Komplikationen, die Langzeit-Nierenfunktion und das {\"U}berleben der pelvinen Exenteration retrospektiv zu analysieren. Es wurde eine Gegen{\"u}berstellung der Behandlungsergebnisse von inkontinenten mit kontinenten Harnableitungen durchgef{\"u}hrt, um das aufwendigere Verfahren der kontinenten Form kritisch betrachten zu k{\"o}nnen. Im Zeitraum von 1992 bis 2013 wurden 64 Exenterationen in der Klinik und Poliklinik f{\"u}r Urologie und Kinderurologie der Universit{\"a}t W{\"u}rzburg aufgrund nicht-urothelialer Malignome durchgef{\"u}hrt. Das mediane Alter des gesamten Patientenkollektivs lag bei 65 Jahren. Hierunter befanden sich 50 vordere und 14 komplette Exenterationen. Eine Harnableitung durch Anlage der inkontinenten Form erfolgte in 39 und durch Anlage der kontinenten Form in 25 F{\"a}llen. Das breite Spektrum der Malignomentit{\"a}ten des gesamten Kollektivs umfasste nicht-urotheliale Malignome der Zervix, des Uterus, der Vulva, der Prostata, der Harnblase und des Darms. Bei 24 Patienten (37,5\%) gelang keine R0-Resektion, und bei 18 Patienten (28,1\%) konnte ein Lymphknotenbefall nachgewiesen werden. Die Fr{\"u}hkomplikationsrate betrug 58,8\%. In einem Zeitraum von 365 Tagen nach Exenteration lag der mediane Clavien-Wert bei 2 Punkten. Die perioperative Sterblichkeit lag bei 0\% und die Tumorprogressionsrate bei 48,4\%. Die Analyse des {\"U}berlebens ergab eine mediane Gesamt{\"u}berlebenszeit von 30 Monaten und eine 5-Jahres-Gesamt{\"u}berlebensrate von 42,7\% {\"u}ber das gesamte Kollektiv hinweg. Die tumorspezifische 5-Jahres{\"U}berlebensrate betrug 55,6\%, und eine R0-Resektion erwies sich als hochsignifikante Einflussgr{\"o}ße bez{\"u}glich der tumorspezifischen {\"U}berlebenszeit. Ein signifikanter Einfluss des Lymphknotenbefalls konnte nicht nachgewiesen werden. Der Einfluss der Komorbidit{\"a}t erwies sich als noch geringer. Die beiden Kollektive der Harnableitungsformen unterschieden sich signifikant in Komorbidit{\"a}tsgrad, OP-Dauer, Hospitalisierungszeit und bez{\"u}glich der Harnableitungskomplikationen. Die Unterschiede der Komorbidit{\"a}t und der OP-Dauer waren sogar hochsignifikant. Dabei wiesen die Patienten mit Anlage eines kontinenten Verfahrens eine niedrigere Komorbidit{\"a}t, eine l{\"a}ngere OP-Dauer, eine l{\"a}ngere Hospitalisierungszeit und prozentual mehr Komplikationen bez{\"u}glich der Harnableitung auf. Weitere wichtige Parameter, in denen sich die Kollektive geringf{\"u}gig unterschieden, waren das Alter und die ASA-Klassifikation. Das Kollektiv mit Anlage einer kontinenten Form war j{\"u}nger und zeigte einen kleineren Wert bez{\"u}glich der pr{\"a}operativen Risikoeinsch{\"a}tzung. Diese Parameter unterschieden sich jedoch nicht signifikant voneinander. Die inkontinente Harnableitung zeigte einen etwas h{\"o}heren Anteil an weiter fortgeschrittenen Tumorstadien, und nur in diesem Kollektiv lagen pr{\"a}operativ Metastasen vor. Bei den Fr{\"u}h- und Sp{\"a}tkomplikationen konnte kein nennenswerter Unterschied zwischen den beiden Kollektiven nachgewiesen werden. Nur um wenige Prozentpunkte war die Fr{\"u}hkomplikationsrate der inkontinenten Form (61,3\%) h{\"o}her als die der kontinenten (55,0\%). Um den Schweregrad der Komplikationen miteinzubeziehen, wurde der mediane Clavien-Wert aller Komplikationen innerhalb von 365 Tagen erfasst. Er betrug in beiden Kollektiven 2 Punkte. Bei der Analyse des {\"U}berlebens zeigte sich, dass das Kollektiv mit Anlage einer kontinenten Form eine knapp {\"u}ber dem Signifikanzlevel h{\"o}here {\"U}berlebenswahrscheinlichkeit sowohl bez{\"u}glich der gesamten als auch der progressionsfreien {\"U}berlebenszeit im Vergleich zu den inkontinenten Verfahren aufwies. Allerdings waren die Unterschiede nicht signifikant und beide Gruppen heterogen bez{\"u}glich des Alters, der Komorbidit{\"a}t, den Tumorstadien und den Malignomentit{\"a}ten. Die vorliegende Studie kommt zu dem Ergebnis, dass R0-Resektionen bei exenterativen Eingriffen eine essentielle Voraussetzung f{\"u}r das langfristige tumorspezifische {\"U}berleben darstellen. In beiden Kollektiven der verschiedenen Harnableitungen zeigte sich kein bedeutsamer Unterschied bez{\"u}glich der Komplikationen. Die geringere OP-Dauer und die geringere Anzahl an Komplikationen mit der Harnableitung sprechen f{\"u}r das inkontinente Verfahren. Die {\"U}berlebensraten zeigten bessere Ergebnisse f{\"u}r die kontinente Form, jedoch waren die Unterschiede nicht signifikant. Dennoch ist eine Bevorzugung des kontinenten Verfahrens, wenn es technisch m{\"o}glich und onkologisch vertretbar ist, nach intensiver Beratung und unter Ber{\"u}cksichtigung des Zustandes sowie der W{\"u}nsche des Patienten durchaus gerechtfertigt. Aufgrund des nichtrandomisierten retrospektiven Charakters dieser Studie, die 2 heterogene Kollektive vergleicht, sollten idealerweise prospektiv angelegte Studien mit gr{\"o}ßerer Patientenanzahl in der Zukunft kl{\"a}ren, ob die hier gefundenen Ergebnisse generelle G{\"u}ltigkeit haben.},
  subject      = {Harnableitung},
  language  = {de}
}